Cevostamab（Cat No.:I042114）is an investigational monoclonal antibody designed to target the FcRH5 (Fc receptor-like 5) protein, which is expressed on the surface of malignant plasma cells, particularly in multiple myeloma. By binding to FcRH5, cevostamab aims to induce immune responses that lead to the destruction of these cancerous cells. This therapy is being studied in clinical trials for the treatment of multiple myeloma, particularly in patients with relapsed or refractory disease. The drug’s potential effectiveness is being evaluated in combination with other therapies to improve patient outcomes and survival rates.
